Clinical trials: Post-exposure Prophylaxis
Occupational Exposure
Knowledge- Attitude- Practice (KAP) of Post Exposure Prophylaxis for Fifth Year Dental Students of a Private Egyptian University
considering the increase number of occupational injuries, The aim of this study is to assess the current level of knowledge, attitude and practice of fifth year dental students as regards post exposure prophylaxis.
- Trial name
- Cross-section (NCT03893383)
- Volunteers
- 420 people
- Sponsor
- Cairo University
Relapsing Fever, Tick-borne, Jarisch Herxheimer Reaction
Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever
Abstract Background Tick-Borne Relapsing Fever (TBRF) is an acute febrile illness. In Israel, TBRF is caused by Borrelia persica and is transmitted by Ornithodoros tholozani ticks.
- Trial name
- NCT00237016
- Testing
- doxycycline treatment
- Where
- Israel
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Medical Corps, Israel Defense Force
Ebola Virus Disease
Prophylaxis Vaccine Antibodies Ebola
Three measures are currently being implemented to control Ebola outbreaks: Monitoring of contacts Isolation and treatment of sick people Vaccination of the population in high-risk areas.
- Trial name
- PROVAE (NCT04822376)
- Testing
- ansuvimab, Ervebo
- Where
- Guinea
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Opioid-use Disorder, Addiction
Competitive Revision for CLARO: Collaboration Leading to Addiction Treatment and Recovery From Other Stresses
The purpose of this study is to develop and then test an enhanced version of the parent study's collaborative care intervention for co-occurring disorders (CC-COD) to reduce the risk of suicide and overdose among individuals with…
- Conditions
- Opioid-use Disorder, Addiction, Depression, Post Traumatic Stress Disorder
- Trial name
- NCT04634279
- Testing
- Collaborative care Plus
- Where
- 12 sites in United States
- Volunteers
- 68 people
- Sponsor
- RAND
Exposure to Human Immunodeficiency Virus (Event)
What Happens in Vegas: PEP to PrEP Opportunities
Observational study looking at barriers to care for individuals seeking care, Post Exposure Prophylaxis (PEP) after an actual or perceived exposure to HIV.
- Trial name
- NCT03775083
- Testing
- Currently approved medications
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Huntridge Family Clinic
Marburg Hemorrhagic Fever
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7288 compared to matched placebo in and to evaluate the pharmacokinetics (PK).
- Trial name
- NCT01566877
- Testing
- AVI-7288
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Post Traumatic Stress Disorder
Efficacy of Single Dose IV Hydrocortisone in Post Traumatic Stress Disorder (PTSD) Prevention
This study is designed to test the hypothesis that a single Hydrocortisone intra venous injection within 6 hours post-trauma facilitates physiological recovery thereby preventing the development of Post Traumatic Stress Disorder…
- Trial name
- NCT00855270
- Testing
- Hydrocortisone
- Where
- Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
HIV-1-infection
The Role of Home Packs of HIV PEPSE in High Risk Individuals
The study is looking at a new way to reduce the risk of catching HIV. Post-exposure Prophylaxis for sexual exposure (PEPSE) is where a month of HIV drugs can be given to reduce the chance of getting HIV, after a risk.
- Trial name
- Home PEPSE (NCT04965662)
- Testing
- Maraviroc, Truvada
- Where
- United Kingdom
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
SARS-CoV Infection
Chemoprevention Clinical Trial of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis
Protocol summary Title A Prospective, randomized, adaptive phase II/III clinical trial, controlled, open-label, chemoprevention, 3-arms, parallel, multi-centred, to A Prospective, randomized, clinical trial, controlled…
- Trial name
- APCC-19 (NCT04597775)
- Testing
- hydroxychloroquine
- Volunteers
- 93 people
- Sponsor
- Regional Center for Disease Control and Prevention, Jordan
Coronavirus Disease 2019 (COVID-19), Post-Exposure Prophylaxis
Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers
Background: The rapid spread and high infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) makes identifying an effective prophylaxis agent highly important.
- Trial name
- NCT04438837
- Testing
- Hydroxychloroquine
- Where
- Israel
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
COVID-19, Corona Virus Infection
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons…
- Conditions
- COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
- Trial name
- NCT04328961
- Testing
- Hydroxychloroquine Sulfate, Ascorbic Acid
- Where
- 8 sites in United States
- Volunteers
- 943 people, healthy volunteers welcome
- Sponsor
- University of Washington
Virus Diseases, Rabies
A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.
The aim of this study is to evaluate the long-term (up to approx.10 years) persistence and to assess the boostability of immune responses in participants who received a primary series of accelerated or conventional rabies PrEP IM…
- Trial name
- NCT02545517
- Testing
- Rabipur, Blood sampling, Purified Chick-Embryo Cell Rabies Vaccine
- Where
- 7 sites in Austria, Germany and 1 more
- Volunteers
- 459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bacillus Anthracis (Anthrax)
Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule
A Phase IV, randomized, multicenter trial to assess the immunogenicity and safety of BioThrax® in varying dose regimens with the primary objective of obtaining information on possible dose-sparing strategies in the event of a…
- Trial name
- NCT01641991
- Testing
- BioThrax®
- Where
- 4 sites in United States
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults
This is an open-label phase 1b clinical trial enrolling people living with HIV (PLWH) who are antiretroviral therapy (ART)-naïve or have not been on ART for > 24 weeks.
- Trial name
- NCT05890963
- Testing
- ART, 10E8.4/iMab, VRC07-523LS
- Where
- Tanzania
- Volunteers
- 20 people
- Sponsor
- David Ho
Rabies
Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
This is a Phase 2b, double blinded, randomized study of SYN023 compared to HyperRab® (a licensed Rabies immune globulin from human sources, HRIG) for the prevention of rabies as part of post-exposure prophylaxis (PEP).
- Trial name
- ARPEP (NCT03961555)
- Testing
- SYN023, HRIG (HyperRab), Rabies vaccine
- Where
- 14 sites in United States, Philippines
- Volunteers
- 448 people
- Sponsor
- Synermore Biologics Co., Ltd.
COVID-19, SARS-CoV 2
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection.
- Trial name
- NCT04372017
- Testing
- Hydroxychloroquine, Vitamin D
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Sanford Health
Viral Hepatitis C
Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers
To assess the safety and tolerability of the use of telaprevir in the setting of post-exposure prophylaxis among HCW exposed to HCV genotype 1 or genotype 2.
- Trial name
- NCT01766115
- Testing
- Telaprevir
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Gonorrhea Male, Chlamydia (Male)
Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM
Men who have sex with men (MSM) are at high risk for gonorrhea and chlamydia in Kenya, where nucleic acid amplification testing is not feasible and most infections therefore go undiagnosed.
- Conditions
- Gonorrhea Male, Chlamydia (Male), Syphilis Male
- Trial name
- NCT06468462
- Testing
- WHO-recommended periodic presumptive treatment, Doxycycline post-exposure prophylaxis
- Where
- 3 sites in Kenya
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- University of Washington
Monkey Pox, Monkey Diseases
Follow-up of People at Risk of Monkeypox Infection: a Prospective Cohort Study
Since one month (first case confirmed the 05/06/2022), some cases of non-imported were reported by Portuguese and British authorities then in several Europeans countries, the US and the Canada.
- Trial name
- MonkeyVax (NCT05438953)
- Testing
- Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)
- Where
- France
- Volunteers
- 164 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infection
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
As a measure of secondary prophylaxis, and with the final objective of avoiding the infection, it has been suggested to use antiretroviral therapy. This is known as post-exposure prophylaxis (PEP).
- Trial name
- RAL-PEP (NCT01576731)
- Testing
- Tenofovir, Emtricitabine, Lopinavir/r, Tenofovir, Emtricitabine, Raltegravir
- Where
- Spain
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona